Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $3 | $3 | $3 | $3 |
| Enterprise Value | $5 | $4 | $3 | $3 |
| Revenue | $3 | $2 | $2 | $2 |
| % Growth | 16.7% | 8.2% | 5.7% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 36.5% | 36.1% | 35.8% | 36.7% |
| EBITDA | $0 | $1 | $0 | $0 |
| % Margin | 15.7% | 20.9% | 19.9% | 19.2% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -4.2% | -3.5% | -5.9% | 0.5% |
| EPS Diluted | -0.38 | -0.48 | -0.86 | 0.07 |
| % Growth | 20.8% | 44.2% | -1,328.6% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |